RxDoctor Payments Data

Ashley Miller

Family · Wichita, KSNPI 1831642040

Payments from drug & device makers

$2,689in general payments, 2019–2025

Across 138 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Collegium Pharmaceutical, Inc.$473
  • AbbVie$277
  • Exeltis, USA Inc.$143
  • Antares Pharma, Inc.$142
  • Vertex$132
  • plus $444 from 12 others

What the payments were for

  • Travel & lodging$2339%
  • Food & beverage$2,41190%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,689 in reported general payments places this provider in the 85th percentile of 1,579 family providers in Kansas.

See all family providers in Kansas

Medicare billing

Part B allowed, 2024
$133,957
Medicare patients
288
Services billed
1,740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl54$29,902
BelbucaBuprenorphine Hcl28$28,393
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen770$23,601
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen536$16,947
MovantikNaloxegol Oxalate19$7,674
Hysingla ErHydrocodone Bitartrate14$6,358
Buprenorphine24$6,214
Pregabalin147$5,296
Gabapentin368$4,453
Oxycodone Hcl270$3,925
Xtampza ErOxycodone Myristate11$3,686
Morphine Sulfate ErMorphine Sulfate134$3,475
Fentanyl29$2,645
Celecoxib35$2,169
Cyclobenzaprine Hcl117$1,938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$473$32,07939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,579 family providers in Kansas.

Other family in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →